{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mutation+Burden", "query": { "intervention": "Mutation Burden" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mutation+Burden&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T04:29:38.402Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04632992", "title": "A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Unresectable or Metastatic Solid Malignancy" ], "interventions": [ { "name": "Entrectinib", "type": "DRUG" }, { "name": "Inavolisib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Trastuzumab Emtansine", "type": "DRUG" }, { "name": "Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" }, { "name": "Investigator's Choice of Chemotherapy", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Pralsetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2021-01-13", "completion_date": "2024-02-27", "has_results": true, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-09-06T04:29:38.402Z", "location_count": 38, "location_summary": "Anchorage, Alaska • Oro Valley, Arizona • Hot Springs, Arkansas + 33 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Oro Valley", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04632992" }, { "nct_id": "NCT05086692", "title": "A Beta-only IL-2 ImmunoTherapY Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Unresectable Solid Tumor", "Clear Cell Renal Cell Carcinoma", "Triple Negative Breast Cancer", "Non-Small Cell Lung Cancer Squamous", "Non-Small Cell Lung Cancer Non-squamous", "Colorectal Cancer (MSI-H)", "Gastric Cancer", "Cervical Cancer", "Basal Cell Carcinoma", "Bladder Cancer", "Merkel Cell Carcinoma", "Squamous Cell Carcinoma of Head and Neck", "Cutaneous Squamous Cell Carcinoma", "Pleural Mesothelioma", "Esophageal Cancer", "Endometrial Carcinoma", "Solid Tumor", "Solid Tumor, Adult", "MSI-H Solid Malignant Tumor", "Cancer With A High Tumor Mutational Burden", "Epithelial Ovarian Carcinoma", "Primary Peritoneal Cancer", "Gastroesophageal Junction (GEJ) Cancer", "Acral Melanoma", "Mucosal Melanoma", "Cutaneous Melanoma", "DMMR Solid Malignant Tumor", "Fallopian Tube Cancer", "Ovarian Cancer", "MSI-H Cancer", "DMMR Cancer", "Pancreas Adenocarcinoma (MSI-H)", "Skin Cancer", "Viral Cancer", "Cervical Cancers", "Endometrial Cancer" ], "interventions": [ { "name": "MDNA11", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medicenna Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2021-08-27", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2025-07-09", "last_synced_at": "2026-09-06T04:29:38.402Z", "location_count": 7, "location_summary": "San Diego, California • San Francisco, California • Santa Monica, California + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05086692" }, { "nct_id": "NCT06941662", "title": "Huntington's Disease Biobank: Advancing Remote Monitoring and Deep Phenotyping", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Huntington Disease" ], "interventions": [ { "name": "computer vision, remote monitoring, blood, urine, wrist bands, mobile-app", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 200, "start_date": "2024-06-01", "completion_date": "2035-12", "has_results": false, "last_update_posted_date": "2025-04-24", "last_synced_at": "2026-09-06T04:29:38.402Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06941662" }, { "nct_id": "NCT02332668", "title": "A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Lymphoma", "Solid Tumor", "Classical Hodgkin Lymphoma", "Microsatellite-instability-high Solid Tumor" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Months to 17 Years" }, "enrollment_count": 370, "start_date": "2015-03-19", "completion_date": "2028-02-02", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-06T04:29:38.402Z", "location_count": 7, "location_summary": "Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02332668" }, { "nct_id": "NCT02282345", "title": "Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Adenocarcinoma", "Deleterious BRCA1 Gene Mutation", "Deleterious BRCA2 Gene Mutation", "HER2/Neu Negative", "Invasive Breast Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2015-04-16", "completion_date": "2022-06-07", "has_results": true, "last_update_posted_date": "2022-07-06", "last_synced_at": "2026-09-06T04:29:38.402Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02282345" }, { "nct_id": "NCT04893083", "title": "A Non-interventional Study for the Collection of Biospecimens From Patients With Parkinson's Disease", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Parkinson Disease" ], "interventions": [], "intervention_types": [], "sponsor": "Neuron23 Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 65, "start_date": "2021-06-28", "completion_date": "2023-09-22", "has_results": false, "last_update_posted_date": "2023-10-30", "last_synced_at": "2026-09-06T04:29:38.402Z", "location_count": 3, "location_summary": "Englewood, Colorado • Farmington Hills, Michigan • Kirkland, Washington", "locations": [ { "city": "Englewood", "state": "Colorado" }, { "city": "Farmington Hills", "state": "Michigan" }, { "city": "Kirkland", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04893083" }, { "nct_id": "NCT05079737", "title": "Sample Collection Study to Assess Prevalence of Gene Mutations: Establishing Population Norms", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Photoaging" ], "interventions": [ { "name": "Mutation Burden", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "DermTech", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 5000, "start_date": "2021-02-12", "completion_date": "2022-09-15", "has_results": false, "last_update_posted_date": "2021-10-15", "last_synced_at": "2026-09-06T04:29:38.402Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05079737" }, { "nct_id": "NCT06090513", "title": "Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Advanced Cancer", "Solid Tumor, Adult", "Myeloid Malignancy" ], "interventions": [ { "name": "Comprehensive Genomic Profile testing; ELIA software; Molecular Genetic Pathologist consultation", "type": "COMBINATION_PRODUCT" }, { "name": "limited genetic testing or no testing", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DIAGNOSTIC_TEST" ], "sponsor": "Bien-Willner Physicians Group PA", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2024-10-18", "completion_date": "2026-10-18", "has_results": false, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-09-06T04:29:38.402Z", "location_count": 1, "location_summary": "Rock Hill, South Carolina", "locations": [ { "city": "Rock Hill", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06090513" }, { "nct_id": "NCT02693535", "title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Multiple Myeloma", "Advanced Solid Tumors" ], "interventions": [ { "name": "Sunitinib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Trastuzumab and Pertuzumab", "type": "DRUG" }, { "name": "Vemurafenib and Cobimetinib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Nivolumab and Ipilimumab", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Talazoparib", "type": "DRUG" }, { "name": "Atezolizumab and Talazoparib", "type": "DRUG" }, { "name": "Tucatinib plus Trastuzumab Subcutaneous (SC)", "type": "DRUG" }, { "name": "Futibatinib", "type": "DRUG" }, { "name": "Dabrafenib plus Trametinib", "type": "DRUG" }, { "name": "Fam-Trastuzumab Deruxtecan-Nxki (TDxD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Society of Clinical Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 4200, "start_date": "2016-03-14", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-06T04:29:38.402Z", "location_count": 174, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Auburn", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02693535" }, { "nct_id": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "ABT-806", "type": "DRUG" }, { "name": "Bemarituzumab", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Standard cytotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2015-01-20", "completion_date": "2020-08-20", "has_results": true, "last_update_posted_date": "2021-04-08", "last_synced_at": "2026-09-06T04:29:38.402Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02213289" } ] }